



## IBA Announces Settlement of Essen Project Litigation

**State of the art proton therapy center in Essen has already treated its first patient**

**Louvain-la-Neuve, Belgium, June 4th 2013** - IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy solutions for the treatment of cancer, is pleased to announce that it has agreed the terms of a settlement agreement in respect to the Essen project litigation with We stdeutsches Protonentherapiezentrum Essen GmbH (WPE). The agreement is subject to final documentation.

Under the terms of the letters of intent, WPE has agreed to purchase the proton therapy center in Essen from STRIBA Protonentherapiezentrum GmbH (STRIBA), the 50/50 joint venture between IBA and STRABAG (Strabag Projektentwicklung GmbH) which was the contracted supplier of the center. The transfer of the center is expected to be completed in the coming weeks, after the signature of the final contracts. In addition, the main terms of an 18 year operations and maintenance agreement have been agreed between IBA and WPE. Further details of the agreements have not been disclosed.

The West German Proton Therapy Center features the world's most advanced proton therapy equipment. The center comprises four treatment rooms, three gantries (isocentric rotational frames) and one fixed-beam room, which offers the most advanced options for patient positioning and irradiation technologies including the latest advancements in IBA's Pencil Beam Scanning (PBS). As previously announced, the center has treated its first patient last week.

**Olivier Legrain, CEO of IBA, commented:** *"We are pleased to be able to bring this project to a conclusion and to deliver a state of the art proton therapy center to German patients. We look forward to a fruitful collaboration with WPE over the coming years and are grateful to our financial partners for the efforts they have made to find a solution to this litigation."*

**-ENDS-**

### **About Proton Therapy**

Proton therapy is increasingly considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumour and sparing healthy surrounding tissue.

As access to proton therapy increases in Europe and across the world, IBA continues to demonstrate compassionate innovations with more patient-friendly treatment rooms and more precise therapies. IBA proton therapy systems account for more than half of the world's clinically based proton therapy facilities. To date they include 15 operational proton therapy centers worldwide, and 10 more centers in development.



### About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment company and the worldwide technology leader in the field of proton therapy. The Company's expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA's leading fully integrated IntegraLab<sup>®</sup> radiopharmacy system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

#### For further information please contact:

##### IBA

**Jean-Marc Bothy**

**Chief Financial Officer**

+32 10 475 890

[Investorrelations@iba-group.com](mailto:Investorrelations@iba-group.com)

**Thomas Ralet**

**Vice-President Corporate Communication**

+32 10 475 890

[thomas.ralet@iba-group.com](mailto:thomas.ralet@iba-group.com)

#### For media and investor enquiries:

##### M:Communications

Mary-Jane Elliott, Amber Bielecka,

Claire Dickinson

+44 (0) 207 920 2333

[IBA@mcomgroup.com](mailto:IBA@mcomgroup.com)